Compounds useful for inhibition of farnesyl protein transferase

Details Compounds useful for inhibition of farnesyl protein transferase Compounds useful for inhibition of farnesyl protein transferase

1998-06-15

2001-04-03

Huang, Evelyn Mei (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S278000, C546S019000, C546S093000

Reexamination Certificate

active

06211193

ABSTRACT:

BACKGROUND
WO 95/10516, published Apr. 20, 1995 discloses tricyclic compounds useful for inhibiting farnesyl protein transferase.
In view of the current interest in inhibitors of farnesyl protein transferase, a welcome. contribution to the art would be compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention.
SUMMARY OF THE INVENTION
This invention provides compounds useful for the inhibition of farnesyl protein transferase (FPT). The compounds of this invention are represented by the formula:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
(A) a represents N or NO
−
;
(B) R
1
and R
3
are the same or different halo atom;
(C) R
2
and R
4
are selected from H and halo, provided that at least one of R
2
and R
4
is H;
(D) the dotted line (---) represents an optional bond;
(E) X is N, C when the optional bond to X is present, or CH when the optional bond to X is absent;
(F) m is 0, 1 or 2;
(G) R represents:
1. a cycloalkyl ring selected from:
2. a heterocycloalkyl ring selected from:
(H) p is 0, 1 or 2;
(I) when n or p is 1 then R
5
is selected from:
(1) ═O, with the proviso that when R is heterocycloalkyl Ring 10.0 and m is 0, 1 or 2 then the ═O group is not bound to a carbon that is adjacent to the ring nitrogen, and with the proviso that when R is heterocycloalkyl Ring 11.0 and m is 1 or 2 then the ═O group is not bound to a carbon that is adjacent to the ring nitrogen;
(2) ═N—OH;
(3) ═N—OR
7
wherein R
7
represents a C
1
to C
6
alkyl group;
(4) ═N—N(H)—C(O)—R
8
wherein R
8
represents —NH
2
or C
1
to C
6
alkyl;
(5) ═N—O—(CH
2
)
r
—C(O)—R
11
wherein r is 1, 2, or 3, and R
11
is selected from: —OH, —O-alkyl or —NH
2
;
(6) ═N—O—(CH
2
)
s
—O—R
12
, wherein s is 2, 3, or 4 and R
12
is selected from: H, alkyl or trialkylsilyl (e.g., Si(CH
3
)
2
—C(CH
3
)
3
);
(7) —NR
13
R
14
wherein R
13
and R
14
are independently selected from:
(a) H;
(b) acyl;
(c) alkyl;
(d) aralkyl;
(d) cycloalkyl;
(e) heterocycloalkyl;
(f) heteroaralkyl;
(g) —S(O)
2
R
15
wherein R
15
is C
1
to C
6
alkyl or aryl; or
(h) an aralkyl, cycloalkyl, heterocycloalkyl, heteroaryl or heteroaralkyl having from 1 to 3 substituents selected from: ═O, halo, —OH or —O-alkyl, wherein said substiuents being bound to substitutable ring carbons; or
(8) OR
16
wherein R
16
is selected from:
(a) H;
(b) C
1
to C
6
alkyl;
(c) —C(O)R
17
wherein R
17
is selected from: alkyl, aryl, heteroaryl or aralkyl; or
(d) —C(O)NHR
18
wherein R
18
is selected from: H, —C(O)R
19
wherein R
19
is selected from: —C(Cl)
3
, alkyl or —(CH
2
)
2
OH;
(J) when n or p is 2, then each R
5
is the same or different and each R
5
is selected from:
(1) —NR
13
R
14
wherein R
13
and R
14
are independently selected from:
(a) H;
(b) acyl;
(c) alkyl;
(d) aralkyl;
(d) cycloalkyl;
(e) heterocycloalkyl;
(f) heteroaralkyl;
(g) —S(O)
2
R
15
wherein R
15
is C
1
to C
6
alkyl or aryl; or
(h) an aralkyl, cycloalkyl, heterocycloalkyl, heteroaryl or heteroaralkyl having from 1 to 3 substituents selected from: ═O, halo, —OH or —O-alkyl, wherein said substiuents being bound to substitutable ring carbons; or;
(2) OR
16
wherein R
16
is selected from:
(a) H;
(b) C
1
to C
6
alkyl;
(c) —C(O)R
17
wherein R
17
is selected from: alkyl, aryl, heteroaryl or aralkyl; or
(d) —C(O)NHR
18
wherein R
18
is selected from: H, —C(O)R
19
wherein R
19
is selected from: —C(Cl)
3
, alkyl or —(CH
2
)
2
OH; or
(K) provided that R
1
is not bound to a carbon atom adjacent to the nitrogen atom in Rings 9.0, 10.0, 11.0 or 12.0;
(L) Y is selected from O or S, provided that each Y is the same;
(M) Z represents the remainder of cycloalkyl Rings 2.0, 3.0 or 4.0, such that spiro ring T is bound to one of the carbon atoms in said cycloalkyl ring;
(N) W represents the remainder of cycloalkyl Ring 5.0, such that spiro ring T is bound to one of the carbon atoms in said cycloalkyl ring;
(O) Q represents the remainder of heterocycloalkyl Rings 9.0, 10.0 or 11.0, such that spiro ring T is bound to one of the carbon atoms in said heterocycloalkyl ring, provided that spiro Ring T is not bound to a carbon atom adjacent to the nitrogen atom; and
(P) R
6
is selected from: alkoxy, alkyl or —OH.
The compounds of this invention: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro; (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras.
The compounds of this invention inhibit farnesyl protein transferase and the farnesylation of the oncogene protein Ras. Thus, this invention further provides a method of inhibiting farnesyl protein transferase, (e.g., ras farnesyl protein transferase) in mammals, especially humans, by the administration of an effective amount of the tricyclic compounds described above. The administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase, is useful in the treatment of the cancers described below.
This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of the tricyclic compounds, described herein, to a mammal (e.g., a human) in need of such treatment. In particular, this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the above described compounds. Examples of tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer.
It is believed that this invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes—i.e., the Ras gene itself is not activated by mutation to an oncogenic form—with said inhibition or treatment being accomplished by the administration of an effective amount of the tricyclic compounds described herein, to a mammal (e.g., a human) in need of such treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes (e.g., neu, src, abl, lck, and fyn), may be inhibited or treated by the tricyclic compounds described herein.
The tricyclic compounds useful in the methods of this invention inhibit or treat the abnormal growth of cells. Without wishing to be bound by theory, it is believed that these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as t

Affiliated with

Also associated with

Rating

Compounds useful for inhibition of farnesyl protein transferase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds useful for inhibition of farnesyl protein transferase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful for inhibition of farnesyl protein transferase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2485402